9 September 2021 08:00 BST
COVID-19 highlights urgent need for national respiratory strategies to drive improvements in patient outcomes and healthcare system resilience
The European Respiratory Society (ERS), the Global Allergy and Airways Patient Platform (GAAPP), AstraZeneca, Amgen and leading respiratory clinicians have launched the International Respiratory Coalition, a new partnership to transform post-pandemic respiratory healthcare.
The Coalition aims to support governments and healthcare systems in their recovery from COVID-19 by strengthening respiratory care. The Coalition will seek to improve outcomes for people living with respiratory diseases by supporting the creation of ambitious national-level respiratory strategies and by building resilience in managing pandemics. Membership is open to organisations and individuals within the respiratory community who share the Coalition’s goals.
Nearly 600 million people globally live with chronic respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and many rare and severe respiratory diseases.1 About four million premature deaths each year have been attributed to chronic respiratory diseases,2 which is double the number of reported deaths from COVID-19 in the first 12 months of the pandemic.3 Prior to the pandemic, progress to improve chronic respiratory diseases care was slow, and in some countries had stagnated over the past decade.4
During the pandemic, some patients with chronic respiratory diseases that contracted COVID-19 were shown to be at greater risk of hospitalisation.5,6 In addition, patients with chronic respiratory diseases faced disruptions to healthcare services and quality care,7 demonstrating new approaches to enable patients to better control their condition, reduce hospitalisations, and ultimately decrease pressure on healthcare systems, are needed.8
Marc Humbert, Professor of Respiratory Medicine at the Université Paris-Saclay, Director of Respiratory and Intensive Care Department (French Reference Centre for Pulmonary Hypertension) at the Hôpital Bicêtre (Assistance Publique Hôpitaux de Paris), Vice Coordinator of the European Reference Network ERN-LUNG, and incoming President of the ERS, said: “The COVID-19 pandemic is having a devastating impact on human health and is revealing gaps in respiratory care that require urgent attention. The European Respiratory Society is excited to be a founding member of the International Respiratory Coalition, working to ensure better respiratory care is central to government and healthcare system recovery plans.”
Tonya Winders, President of GAAPP, said: “Nearly 600 million people worldwide live with chronic respiratory diseases. Unfortunately, few countries have national respiratory strategies to improve treatment and help patients control their disease and achieve better outcomes. The International Respiratory Coalition will play a critical role in addressing the longstanding under-prioritisation of chronic respiratory diseases within healthcare systems in the year ahead.”
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit of AstraZeneca, said: “The International Respiratory Coalition has an important opportunity to reduce morbidity and mortality in respiratory disease while building healthcare system resilience. AstraZeneca has been committed to advancing respiratory science and care for more than 50 years and we are excited to contribute to this important initiative to support patients who are underserved today.”
Darryl Sleep, Senior Vice President, Global Medical and Chief Medical Officer of Amgen, said: “While COVID-19 exposed the staggering health disparities and disproportionate burden on racial and ethnic minorities and other groups historically underserved by healthcare systems, these same communities have long felt the negative impact of respiratory disease. This partnership with the International Respiratory Coalition will help Amgen in our mission to serve patients, which includes working within communities to remove the barriers that prevent patients from living their healthiest lives.”
Chronic respiratory diseases
Chronic respiratory diseases, including asthma, COPD, bronchiectasis and others, represent a significant and growing burden on individuals, societies, and healthcare systems around the world.2 Nearly 600 million people globally live with chronic respiratory diseases,1 however this figure is likely underestimated as many people remain undiagnosed.8 In recent decades, the burden of respiratory diseases has increased as a result of health inequalities, environmental factors, and growing and aging populations, threatening health system resilience to external challenges.8
International Respiratory Coalition
The International Respiratory Coalition was formed to address existing challenges in respiratory healthcare services that were exacerbated by the emergence of COVID-19 and seeks the prioritisation of respiratory care reform by governments and national healthcare systems. The Coalition will implement a multi-stakeholder, collaborative approach to working with governments to create or improve national respiratory strategies.
The International Respiratory Coalition is coordinated by the European Respiratory Society, in partnership with the Global Allergy & Airways Patient Platform, AstraZeneca, Amgen and other organisations with an interest in respiratory health. Each partner will provide funding or contributions of time and expertise to deliver the aims of the Coalition at a global or national level.
For more information, visit the ERS website.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
1. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med, 2020 Jun;8(6):585-596.
2. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017. Available online via https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf. Accessed July 2021.
3. Carvalho, T., Krammer, F., & Iwasaki, A. The first 12 months of COVID-19: a timeline of immunological insights. Nature Reviews Immunology. 2021:245–256. https://doi.org/10.1038/s41577-021-00522-1
4. Commissions from the Lancet journals. After asthma: redefining airways diseases. After asthma: redefining airways diseases (thelancet.com). 12 September 2017. Available at: https://www.thelancet.com/commissions/asthma.
5. Gerayeli FV, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021; 33: 100789.
6. Huang BZ, et al. Asthma Disease Status, COPD, and COVID-19 Severity in a Large Multiethnic Population. J Allergy Clin Immunol Pract. 2021. https://doi.org/10.1016/j.jaip.2021.07.030
7. World Health Organisation. COVID-19 and NCDs. Available at: https://cdn.who.int/media/docs/default-source/ncds/ncd-covid-19/for-web---rapid-assessment---29-may-2020-(cleared)_125bf384-9333-40c9-aab2-c0ecafb76ab2.pdf?sfvrsn=6296324c_20. Accessed August 2021.
8. AstraZeneca. A Blueprint for Change. Available at: http://www3.weforum.org/docs/WEF_Blueprint_for_change_Chronic_airway_disease.pdf. Accessed August 2021.
Veeva ID: Z4-36514
Date of Preparation: August 2021